American Oncology Network Inc-A 2024年度报告

FORM10-K xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedDecember31, 2024oroTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number001-04321 American Oncology Network, Inc.(Exact name of registrant as specified in its charter) Delaware Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to section 12(g) of the Act: NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yeso Nox Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yeso Nox Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subjectto such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive DataFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (orfor such shorter period that the registrant was required to submit and post such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the ExchangeAct. Large accelerated fileroAccelerated fileroNon-accelerated filerxSmaller reporting companyxEmerging growth companyo If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements.o Indicate by check mark whether any of those error corrections are restatements that required analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).YesoNox The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, as of June 30, 2024, the last dayof the registrant’s most recently completed second fiscal quarter, was approximately $7,988,383. As of March 24, 2025, the registrant had outstanding32,087,737shares of Class A common stock, inclusive of the Sponsor Earnout shares, and14,867,850shares of Class B common stock. TABLE OF CONTENTS PAGECautionary Note Regarding Forward-Looking Statements1Part I2Item 1. Business2Item 1A. Risk Factors13Item 1B. Unresolved Staff Comments39Item 1C. Cybersecurity39Item 2. Properties41Item 3. Legal Proceedings42Item 4. Mine Safety Disclosures42Part II43Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities43Item 6. [Reserved]43Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations44Item 7A. Quantitative and Qualitative Disclosures About Market Risk56Item 8. Financial Statements and Supplementary Data56Report of Independent Registered Public Accounting Firm58Consolidated Balance Sheets60Consolidated Statements of Operations and Comprehensive Income (Loss)62Consolidated Statements of Mezzanine and Stockholders’ Equity64Consolidated Statements of Cash Flows66Notes to Consolidated Financial Statements68Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures114Item 9A. Controls and Procedures114Item 9B. Other Information118Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections118Part III119Item 10. Directors, Executive Officers and Corporate Governance119Item 11. Executive Compensation124Item 12. Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters127Item 13. Certain Relationships and Related Transactions, and Director Independence129Item 14. Principal Ac